# Efficacy and Safety Study of Oral Fludarabine Phosphate in Combination With Mitoxantrone as First Line Treatment in Follicular NHL

> **NCT00185445** · PHASE2 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 62 (actual)

## Conditions studied

- Non Hodgkin Lymphoma

## Interventions

- **DRUG:** Fludarabine Phosphate (Fludara)

## Key facts

- **NCT ID:** NCT00185445
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06
- **Primary completion:** 2006-10
- **Final completion:** 2006-10
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2013-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00185445

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00185445, "Efficacy and Safety Study of Oral Fludarabine Phosphate in Combination With Mitoxantrone as First Line Treatment in Follicular NHL". Retrieved via MORVS 2026-10-15 from https://api.morvs.ai/clinical/NCT00185445. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*